Recent trends in the epidemiology and clinical outcomes of inflammatory bowel disease in South Korea, 2010-2018open access
- Authors
- Kim, Seulji; Lee, Hyun Jung; Lee, Seung Woo; Park, Sanghyun; Koh, Seong-Joon; Im, Jong Pil; Kim, Byeong Gwan; Han, Kyung-Do; Kim, Joo Sung
- Issue Date
- Mar-2024
- Publisher
- Baishideng Publishing Group Inc
- Keywords
- Crohn's disease; Incidence; Inflammatory bowel disease; Prevalence; Ulcerative colitis
- Citation
- World Journal of Gastroenterology, v.30, no.9, pp 1154 - 1163
- Pages
- 10
- Journal Title
- World Journal of Gastroenterology
- Volume
- 30
- Number
- 9
- Start Page
- 1154
- End Page
- 1163
- URI
- https://scholarworks.bwise.kr/ssu/handle/2018.sw.ssu/49614
- DOI
- 10.3748/wjg.v30.i9.1154
- ISSN
- 1007-9327
2219-2840
- Abstract
- BACKGROUND Inflammatory bowel disease (IBD) was previously regarded as a Western disease; however, its incidence is increasing in the East. The epidemiology of IBD in Asia differs significantly from the patterns in the West. AIM To comprehensively investigate the epidemiology of IBD in South Korea, including its incidence, prevalence, medication trends, and outcomes. METHODS We analyzed claims data from the Health Insurance Review and Assessment Service and Rare and Intractable Diseases (RIDs), operated by the National Health Insurance Service of South Korea. Patients with IBD were identified based on the International Classification of Diseases, Tenth Revision, and RID diagnostic codes for Crohn's disease (CD) and ulcerative colitis (UC) from 2010 to 2018. RESULTS In total, 14498 and 31409 patients were newly diagnosed with CD and UC, respectively, between 2010 and 2018. The annual average incidence of CD was 3.11 cases per 105 person-years, and that of UC was 6.74 cases per 105 personyears. Since 2014, the incidence rate of CD has been stable, while that of UC has steadily increased, shifting the peak age group from 50-year-olds in 2010 to 20-cylates and corticosteroids gradually decreased, while that of immunomodulators and biologics steadily increased in both CD and UC. The clinical outcomes of IBD, such as hospitalization and surgery, decreased during the study period. CONCLUSION The CD incidence has been stable since 2014, but that of UC has increased with a shift to a younger age at peak incidence between 2010 and 2018. IBD clinical outcomes improved over time, with increased use of immunomodulators and biologics. © The Author(s) 2024.
- Files in This Item
-
Go to Link
- Appears in
Collections - ETC > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/ssu/handle/2018.sw.ssu/49614)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.